Beth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA.
Medical College of Wisconsin, Wauwatosa, WI, USA.
Best Pract Res Clin Anaesthesiol. 2020 Sep;34(3):507-516. doi: 10.1016/j.bpa.2020.06.007. Epub 2020 Jul 3.
Chronic pain is typically defined as pain that persists after acute tissue damage and inflammation or as pain that follows a chronic disease process and lasts more than three months. Because of its debilitating impact on the quality of life of patients, recent research aims to investigate the mechanisms behind nociception to discover novel therapeutic agents to alleviate pain. One such target is the neuropeptide calcitonin gene-related peptide (CGRP), which has shown to play an integral role in migraine pathophysiology. Effective treatments of migraines with CGRP antagonists have stimulated our efforts toward checking a possible involvement of CGRP in nonheadache pain conditions such as hypertension, congestive heart failure, Alzheimer's disease, and vascular ischemia. Here, we provide a brief overview of chronic pain, with a particular emphasis on the role of CGRP as a fundamental mediator of nociceptive pain as well as a target for novel therapeutic agents.
慢性疼痛通常被定义为急性组织损伤和炎症后持续存在的疼痛，或作为一种慢性疾病过程的疼痛，并持续超过三个月。由于它对患者生活质量的不良影响，最近的研究旨在调查伤害感受背后的机制，以发现缓解疼痛的新型治疗药物。一种这样的目标是降钙素基因相关肽（CGRP），它在偏头痛病理生理学中起着不可或缺的作用。CGRP 拮抗剂对偏头痛的有效治疗刺激了我们的努力，以检查 CGRP 是否可能参与非头痛疼痛状况，如高血压、充血性心力衰竭、阿尔茨海默病和血管缺血。在这里，我们提供了慢性疼痛的简要概述，特别强调 CGRP 作为伤害感受性疼痛的基本介质以及新型治疗药物的靶标。
